Vernalis Announces Successful Completion of Study

WINNERSH, UNITED KINGDOM--(Marketwired - Feb 24, 2014) -

24 February 2014
LSE: VER


      Vernalis Announces Successful Completion of Second Pivotal
     Bioavailability Study with First Cough Cold Product, CCP-01

Vernalis plc today announces successful completion of the second and
final CCP-01 pivotal comparative bioavailability study. This positive
multi-dose study follows successful completion of the single dose study
announced in November last year.CCP-01 is the first product being developed
for Vernalis by Tris Pharma
for the US prescription cough cold market. Both pivotal comparative
bioavailability studies required to support an NDA filing in mid-2014
have now been completed successfully. In addition to these studies, the
NDA will be supported by data from a 12-month stability programme for
which positive interim 6-month stability data has already been
generated.

Under the deal announced in February 2012, Vernalis is paying Tris
Pharma to develop up to six unique extended release equivalents to
existing immediate release prescription cough cold treatments. The
financial terms of this licensing deal have not been disclosed.

Ian Garland, CEO of Vernalis commented "We are delighted with these
further positive results that complete the critical clinical component
of the mid-2014 NDA filing. We look forward to completion of the
on-going stability study and the filing of our first NDA from our
collaboration with Tris".


                            -- ends --

Enquiries:

Vernalis plc:
Ian Garland, Chief Executive Officer                +44 (0) 118 938 0015
David Mackney, Chief Financial Officer


Canaccord Genuity Limited:                          +44 (0) 20 7523 8350
Lucy Tilley
Dr Julian Feneley
Henry Fitzgerald-O'Connor


Brunswick Group:                                    +44 (0) 20 7404 5959
Jon Coles


Notes to Editors


About Vernalis
Vernalis is a revenue generating development stage pharmaceutical
company with significant expertise in drug development. The Group has
one marketed product, frovatriptan for the acute treatment of migraine,
an exclusive licensing agreement to develop and commercialise multiple
novel products focussed on the US prescription cough cold market as
well as seven programmes in its NCE development pipeline. Vernalis has
also significant expertise in fragment and structure based drug
discovery which it leverages to enter into collaborations with larger
pharmaceutical companies. The Company's technologies, capabilities and
products have been endorsed over the last five years by collaborations
with leading pharmaceutical companies, including Biogen Idec, Endo,
GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit  www.vernalis.com 


Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect
the Company's current expectations regarding future events including
the clinical development and regulatory clearance of the Company's
products, the Company's ability to find partners for the development
and commercialisation of its products, as well as the Company's future
capital raising activities. Forward-looking statements involve risks
and uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors including the
success of the Company's research strategies, the applicability of the
discoveries made therein, the successful and timely completion of
clinical studies, the uncertainties related to the regulatory process,
the ability of the Company to identify and agree beneficial terms with
suitable partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from such
transactions, the acceptance of frovatriptan and other products by
consumers and medical professionals, the successful integration of
completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to
identify and consummate suitable strategic and business combination
transactions.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END